Tomonori Nakazato, Masao Hagihara, Naohi Sahara, Yotaro Tamai, Ryuji Ishii, Shigehisa Tamaki, Atsushi Wake, Kenji Tajika, Rika Sakai, Takeshi Kobayashi, Jian Hua, Morihiro Inoue, Yoshinobu Aisa, Shin Fujisawa, Koji Miyazaki, Seiji Irie, Eri Tanaka, Masaaki Higashihara
The Vulnerable Elders Survey-13 (VES-13) is a well-studied simplified frailty screening tool for elderly patients in the oncology setting. We conducted a prospective clinical trial to evaluate the efficacy and safety of dose-adjusted treatment based on the VES-13 in transplant-ineligible patients with newly diagnosed multiple myeloma (MM). In the Fit group (VES-13 <3), patients were treated with 4 cycles of standard-dose VCD (bortezomib, cyclophosphamide, and dexamethasone) followed by 4 cycles of standard-dose VTD (bortezomib, thalidomide, and dexamethasone)...
July 31, 2021: Annals of Hematology